Catalent
NEWS
Berkeley Lights calls itself a digital cell biology company. It develops and markets tech platforms for what it calls “the intersection of biology, technology and information.”
Following the U.S. Drug Enforcement Agency’s rescheduling of GW Pharmaceuticals’ Epidiolex from a Schedule I to a Schedule V, other cannabis-based drug development companies believe there is momentum for their medications to gain regulatory approval.
Biohaven Pharma, headquartered in New Haven, Conn., announced positive data from a proof-of-concept trial for its BHV-0223 in social anxiety and public speaking anxiety disorders.
JOBS
IN THE PRESS